Patent search ap:("AMGEN INC.") AND inv:"Longbin Liu" Page 1

1.

发明授权
Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use 有权

公开(公告)号：US10246429B2

公开(公告)日：2019-04-02

申请号：US15749895

申请日：2016-08-04

Applicant: AMGEN INC.

Inventor： Jennifer R. Allen , Albert Amegadzie , Matthew P. Bourbeau , James A. Brown , Ning Chen , Michael J. Frohn , Longbin Liu , Qingyian Liu , Liping H. Pettus , Wenyuan Qian , Corey M. Reeves , Aaron C. Siegmund

IPC: C07D417/10 , C07D279/08 , C07D417/14 , C07D471/04 , C07D491/056 , A61P25/28 , A61P25/00 , A61P25/16 , C07D491/08 , C07D491/107 , C07D498/10 , C07F7/08

Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 and R10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.

2.

发明授权
KRAS G12C inhibitors and methods of using the same 有权

公开(公告)号：US11090304B2

公开(公告)日：2021-08-17

申请号：US16402538

申请日：2019-05-03

Applicant: Amgen Inc.

Inventor： John Gordon Allen , Jennifer Rebecca Allen , Ana Elena Minatti , Qiufen Xue , Ryan Paul Wurz , Christopher M. Tegley , Alexander J. Pickrell , Thomas T. Nguyen , Vu Van Ma , Patricia Lopez , Longbin Liu , David John Kopecky , Michael J. Frohn , Ning Chen , Jian Jeffrey Chen , Aaron C. Siegmund , Albert Amegadzie , Nuria A. Tamayo , Shon Booker , Clifford Goodman , Mary Walton , Nobuko Nishimura , Youngsook Shin , Jonathan D. Low , Victor J. Cee , Anthony B. Reed , Hui-Ling Wang , Brian Alan Lanman

IPC: A61K31/517 , A61P35/00 , A61K31/4985 , A61K39/395 , C07D403/04 , C07D471/04

Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

3.

发明授权
KRAS G12C inhibitors and methods of using the same 有权

公开(公告)号：US10519146B2

公开(公告)日：2019-12-31

申请号：US15984855

申请日：2018-05-21

Applicant: Amgen Inc.

Inventor： Brian Alan Lanman , Jian Chen , Anthony B. Reed , Victor J. Cee , Longbin Liu , David John Kopecky , Patricia Lopez , Ryan Paul Wurz , Thomas T. Nguyen , Shon Booker , Nobuko Nishimura , Youngsook Shin , Nuria A. Tamayo , John Gordon Allen , Jennifer Rebecca Allen

IPC: C07D471/04 , C07D487/04 , C07D403/04 , C07D401/04 , C07D475/00 , A61K31/496 , A61K31/519 , A61P35/00 , C07D417/04 , A61K38/07 , C07D487/08 , C07D417/12 , C07D513/04 , C07D487/10 , C07D239/80 , C07D401/14 , C07D237/34 , A61K31/416 , A61K31/55 , A61K31/454 , A61K31/517 , A61K31/502 , A61K31/5025 , A61K31/7068 , C07D275/04

Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

4.

发明授权
Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use 有权
Title translation: 环丙基稠合噻嗪-2-胺化合物作为β-分泌酶抑制剂和使用方法

公开(公告)号：US09550762B2

公开(公告)日：2017-01-24

申请号：US14819256

申请日：2015-08-05

Applicant: AMGEN INC.

Inventor： Jennifer R. Allen , Albert Amegadzie , Matthew P. Bourbeau , James A. Brown , Jian J. Chen , Yuan Cheng , Michael J. Frohn , Angel Guzman-Perez , Paul E. Harrington , Longbin Liu , Qingyian Liu , Jonathan D. Low , Vu Van Ma , James Manning , Ana Elena Minatti , Thomas T. Nguyen , Nobuko Nishimura , Mark H. Norman , Liping H. Pettus , Alexander J. Pickrell , Wenyuan Qian , Shannon Rumfelt , Robert M. Rzasa , Aaron C. Siegmund , Markian M. Stec , Ryan D. White , Qiufen Xue

IPC: C07D417/12 , C07D417/14 , C07D471/04 , C07D513/10 , C07D417/04 , C07D279/08

CPC classification number: C07D417/12 , C07D279/08 , C07D417/04 , C07D417/14 , C07D471/04 , C07D513/10

Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

Abstract translation: 本发明提供了一类可用于调节β-分泌酶（BACE）活性的化合物。所述化合物具有通式I：其中式I中的变量A4，A5，A6，A8以及R 1，R b，R 1，R 2，R 3和R 7各自独立地定义。本发明还提供包含该化合物的药物组合物，以及该化合物和组合物用于治疗由BACE的生物学活性产生的与A-β斑块形成和沉积有关的病症和/或病症的用途。这种BACE介导的疾病包括例如阿尔茨海默病，认知缺陷，认知障碍，精神分裂症和其他中枢神经系统疾病。本发明还提供式II和III的化合物及其分子式实施方案，用于制备本发明化合物的中间体和方法。

5.

发明授权
KRAS G12C inhibitors and methods of using the same 有权

公开(公告)号：US11905281B2

公开(公告)日：2024-02-20

申请号：US17031607

申请日：2020-09-24

Applicant: Amgen Inc.

Inventor： Brian Alan Lanman , Jian Chen , Anthony B. Reed , Victor J. Cee , Longbin Liu , David John Kopecky , Patricia Lopez , Ryan Paul Wurz , Thomas T. Nguyen , Shon Booker , Nobuko Nishimura , Youngsook Shin , Nuria A. Tamayo , John Gordon Allen , Jennifer Rebecca Allen

IPC: C07D471/04 , C07D213/82 , C07D417/04 , A61K38/07 , C07D487/08 , C07D417/12 , C07D513/04 , C07D487/10 , C07D487/04 , C07D401/04 , C07D239/80 , C07D401/14 , C07D237/34 , C07D403/04 , A61K31/496 , A61K31/416 , A61K31/55 , A61K31/454 , A61K31/519 , A61K31/502 , A61K31/517 , A61K31/5025 , A61P35/00 , A61K31/7068 , C07D275/04 , C07D475/00

CPC classification number: C07D417/04 , A61K31/416 , A61K31/454 , A61K31/496 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61K31/55 , A61K31/7068 , A61K38/07 , A61P35/00 , C07D237/34 , C07D239/80 , C07D275/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D417/12 , C07D471/04 , C07D475/00 , C07D487/04 , C07D487/08 , C07D487/10 , C07D513/04

Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

6.

发明授权
1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use 有权

公开(公告)号：US11021493B2

公开(公告)日：2021-06-01

申请号：US16466207

申请日：2017-12-13

Applicant: AMGEN INC.

Inventor： Jennifer R. Allen , Matthew P. Bourbeau , James A. Brown , Ning Chen , Michael J. Frohn , Zice Fu , Longbin Liu , Qingyian Liu , Liping H. Pettus , Wenyuan Qian , Corey Reeves , Aaron C. Siegmund

IPC: C07D513/08 , A61P25/28 , C07D417/10

Abstract: The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2′, R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.

7.

发明授权
Fused heterocyclic derivatives and methods of use 有权

公开(公告)号：US09066954B2

公开(公告)日：2015-06-30

申请号：US13916984

申请日：2013-06-13

Applicant: Amgen Inc.

Inventor： Brian K. Albrecht , David Bauer , Steven Bellon , Christiane M. Bode , Shon Booker , Alessandro Boezio , Deborah Choquette , Derin D'Amico , Jean-Christophe Harmange , Satoko Hirai , Randall W. Hungate , Tae-Seong Kim , Richard T. Lewis , Longbin Liu , Julia W. Lohman , Mark H. Norman , Michele Potashman , Aaron C. Siegmund , Stephanie K. Springer , Markian Stec , Ning Xi , Kevin Yang

IPC: C07D487/04 , C07D403/12 , A61K31/4192 , A61K31/4353 , A61K31/4709 , A61P35/00 , A61K31/538 , C07D471/04 , C07D493/04 , C07D495/04 , C07D498/04 , C07D519/00 , A61K31/437 , A61K31/497 , A61K31/5025 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K45/06 , C07D473/34

CPC classification number: A61K31/538 , A61K31/437 , A61K31/497 , A61K31/5025 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K45/06 , C07D403/12 , C07D471/04 , C07D473/34 , C07D487/04 , C07D493/04 , C07D495/04 , C07D498/04 , C07D519/00

Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

8.

发明授权
Inhibitors of PI3 kinase and/or mTOR 有权
Title translation: PI3激酶抑制剂和/或mTOR

公开(公告)号：US08772480B2

公开(公告)日：2014-07-08

申请号：US13681230

申请日：2012-11-19

Applicant: Amgen Inc.

Inventor： Kristin L. Andrews , Yunxin Y. Bo , Shon Booker , Victor J. Cee , Noel D'Angelo , Bradley J. Herberich , Fang-Tsao Hong , Claire L. M. Jackson , Brian Alan Lanman , Hongyu Liao , Longbin Liu , Nobuko Nishimura , Mark H. Norman , Liping H. Pettus , Anthony B. Reed , Adrian Leonard Smith , Seifu Tadesse , Nuria A. Tamayo , Bin Wu , Ryan Wurz , Kevin C. Yang

IPC: C07D401/04 , C07D401/14 , A61K31/444 , A61K31/53 , A61P35/00

CPC classification number: C07D473/00 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐; 使用该化合物治疗疾病或病症如癌症的方法; 和含有这些化合物的药物组合物，其中变量如本文所定义。